The battle to combat counterfeit drugs; documents detail problems at Novartis facility

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by         STAT+: While a law designed to thwart counterfeit medicines lurches into full force, fake pills keep circulating By Ed Silverman and Jonathan Wosen Alex Hogan/STAT, Adobe Gilead and Johnson & Johnson have been hit by a sweeping and sophisticated counterfeit drug scheme involving HIV medicines. Read More STAT+: Documents show problems at Novartis facility where cancer drug production was halted By Ed Silverman FABRICE COFFRINI/AFP/Getty Images Documents reviewed by STAT illustrate issues at a Novartis facility where production of a cancer treatment was halted this month. Read More STAT+: The American Medical Association is fighting an otherwise popular bill to require training doctors about opioid use disorder By Nicholas Florko Adobe The American Medical Association is fighting an otherwise popular bill that would require training doctors about opioid use disorder. Read More Sponsor content by REGULATORY AFFAIRS PROFESSIONALS SOCIETY (RAPS) How will the rapidly changing regulatory landscape affect your submissions? Understanding the implications of new and changing regulations in bringing drug products to market is essential for regulatory affairs professionals. Build a solid foundation of the latest knowledge with a Regulatory Affairs Certificate in Pharmaceuticals, where you'll learn how to navigate the rapidly evolving regulatory landscape. The certificate program features a series of nine self-paced online courses, including five electives spanning the topical areas of pharmaceuticals, quality, clinical, biologics, and the regulatory profession. Learn more. STAT+: Former AstraZeneca executive accused of insider trading over Daiichi cancer drug deal By Ed Silverman BRYAN R. SMITH/AFP via Getty Images A former AstraZeneca communications executive was accused of insider trading in connection with a partnership with Daiichi Sankyo. Read More Tuesday, May 31, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser